Outcome of the Board Meeting dated 05th May 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sandu Pharmaceuticals reported standalone audited financial results for FY 2025-26 with revenue from operations at Rs 16,853.4 lakhs, up from Rs 14,069.3 lakhs in the previous year (approx 20% revenue growth). However, profit after tax declined significantly to Rs 975.1 lakhs from Rs 1,765.1 lakhs in the prior year, showing approximately 45% PAT decline. The board recommended a final dividend of Rs 1 per equity share (10% on face value of Rs 10), subject to shareholder approval. The company appointed M/s Shekhar Joshi & Co as Cost Auditor for FY 2026-27 and reappointed internal auditors for Goa and Mumbai operations. The statutory auditor issued an unmodified opinion on the financial statements. The company confirmed it is not a 'Large Corporate' under SEBI guidelines and has no outstanding borrowings.
Despite ~20% revenue growth, the significant ~45% decline in profitability is a concern for shareholders. The dividend recommendation provides some investor return, while the clean audit opinion offers some comfort on financial reporting quality.